Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

The company has a forward P/E ratio of 11.5 while Merck, Eli Lilly, and Novo Nordisk have multiples of 14.8, 64, and 40.5.

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. Vandana Singh Qorvo Soars 7% After ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

Every investor in Pfizer Inc. ( NYSE:PFE) should be aware of the most powerful shareholder groups. We can see that ...

PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 billion through balance sheet optimization. Investing $10.7-$11.7 billion in R&D, focusing on obesity treatments ...

Pfizer Inc. (NYSE:PFE) will increase its dividend from last year's comparable payment on the 7th of March to $0.43. This will take the annual payment to 6.5% of the stock price, which is above ...

Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to PFE's higher yield.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xencor (XNCR – Research Report) and Pfizer (PFE – Research Report). Discover outperforming stocks and invest ...